[HTML][HTML] Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 …
Background COVID-19 is a viral prothrombotic respiratory infection. Heparins exert
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
S Barco, D Voci, U Held, T Sebastian… - The Lancet …, 2022 - europepmc.org
Background COVID-19 is a viral prothrombotic respiratory infection. Heparins exert
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
[HTML][HTML] Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 …
S Barco, D Voci, U Held, T Sebastian… - The Lancet …, 2022 - ncbi.nlm.nih.gov
Background COVID-19 is a viral prothrombotic respiratory infection. Heparins exert
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
S Barco, D Voci, U Held, T Sebastian… - The Lancet …, 2022 - pubmed.ncbi.nlm.nih.gov
Background COVID-19 is a viral prothrombotic respiratory infection. Heparins exert
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
[PDF][PDF] Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 …
S Barco, D Voci, U Held, T Sebastian, R Bingisser… - 2022 - access.archive-ouverte.unige.ch
Background COVID-19 is a viral prothrombotic respiratory infection. Heparins exert
antithrombotic and antiinflammatory effects, and might have antiviral properties. We aimed to …
antithrombotic and antiinflammatory effects, and might have antiviral properties. We aimed to …
[PDF][PDF] Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 …
S Barco, D Voci, U Held, T Sebastian, R Bingisser… - 2022 - researchgate.net
Background COVID-19 is a viral prothrombotic respiratory infection. Heparins exert
antithrombotic and antiinflammatory effects, and might have antiviral properties. We aimed to …
antithrombotic and antiinflammatory effects, and might have antiviral properties. We aimed to …
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
S Barco, D Voci, U Held, T Sebastian, R Bingisser… - The Lancet …, 2022 - Elsevier
Background COVID-19 is a viral prothrombotic respiratory infection. Heparins exert
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
S Barco, D Voci, U Held, T Sebastian… - The Lancet …, 2022 - boris.unibe.ch
BACKGROUND COVID-19 is a viral prothrombotic respiratory infection. Heparins exert
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
S Barco, D Voci, U Held, T Sebastian… - The Lancet …, 2022 - zora.uzh.ch
Background: COVID-19 is a viral prothrombotic respiratory infection. Heparins exert
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
antithrombotic and anti-inflammatory effects, and might have antiviral properties. We aimed …
[PDF][PDF] Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 …
S Barco, D Voci, U Held, T Sebastian, R Bingisser… - 2022 - researchgate.net
Background COVID-19 is a viral prothrombotic respiratory infection. Heparins exert
antithrombotic and antiinflammatory effects, and might have antiviral properties. We aimed to …
antithrombotic and antiinflammatory effects, and might have antiviral properties. We aimed to …